Nebivolol, CAS# 99200-09-6, is recognized as the brand name anti-hypertensive drug Bystolic, which is marketed by Forest Pharmaceuticals, Inc. This beta-blocker powerhouse has a patent expiration of June 2, 2015, and is projected to become a widely used generic treatment for chronic hypertension. Current dosages of Bystolic, or nebivolol, 2.5, 5, 10, and 20 milligram tablets. Patients are advised to take nebivolol with food, and accelerate dosing should be avoided. The recommended starting dose is 5 milligrams to be taken once daily, and only increased at 2-week intervals, but no greater then 40 milligrams daily. Nebivolol has proven to be effectual as a monotherapy or in conjunction with other medications. Side effects reported include insomnia, nausea, headache, diarrhea and fatigue.
With a significant vasodilatation action due to the activity of nitric oxide, nebivolol is considered to be an unparalleled treatment for hypertension. Nebivolol is successful at reducing arterial pressure values with greater patient tolerability. The Journal of Clinical Hypertension published results from a study comparing nebivolol and lisinopril on June 4, 2012. This trial was executed to ascertain if the diastolic blood pressure lowering effects of the combination of nebivolol and lisinopril, given as separate doses, were more efficacious than nebivolol and lisinopril used in the same doses, or in combination. This study involoved men and women, with stage 2 diastolic hypertension, who were untreated for this condition. Of the 1,126 patients enrolled in this double blind and placebo controlled study, few adverse effects were found, and no deaths occurred. Researchers concluded that overall the combination of both lisinopril and nebivolol were most effective when used in combination, rather then as montherapy. The patients in the group who received both medications displayed a lower blood pressure overall, as well as tolerability lisinopril and nebivolol used in together. LGM Pharma is a provider of both nebivolol and lisinopril for research and development purposes.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.